Literature DB >> 17880843

Repeated botulinum toxin injection for idiopathic overactive bladder: will chemodenervation become a long-term solution?

Darius J Unwala, Paholo Barboglio, Angelo E Gousse.   

Abstract

Botulinum toxin A (BTX-A) has emerged as a novel treatment option for idiopathic overactive bladder (OAB) refractory to antimuscarinic agents. The clinical needs of refractory OAB patients have been recently met by sacral neuromodulation and augmentation enterocystoplasty. Important features of BTX-A should include safety, efficacy, and ease of delivery during long-term repeated usage. This article reviews the role of repeated BTX-A injections in the treatment of idiopathic OAB.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17880843     DOI： 10.1007/s11934-007-0041-5

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


  32 in total

1.  Treatment of neurogenic incontinence with botulinum toxin A.

Authors:  B Schurch; D M Schmid; M Stöhrer
Journal:  N Engl J Med       Date:  2000-03-02       Impact factor: 91.245

2.  Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.

Authors:  D M Schmid; P Sauermann; M Werner; B Schuessler; N Blick; M Muentener; R T Strebel; D Perucchini; D Scheiner; G Schaer; H John; A Reitz; D Hauri; B Schurch
Journal:  J Urol       Date:  2006-07       Impact factor: 7.450

3.  Antibodies against botulinum neurotoxin type A as a cause of treatment failure after the first detrusor injection.

Authors:  Heinrich Schulte-Baukloh; Hans Bigalke; Gert Heine; Daniela Pape; Burkard Stuerzebecher; Kurt Miller; Helmut H Knispel
Journal:  Urology       Date:  2007-03       Impact factor: 2.649

Review 4.  Management of bladder, prostatic and pelvic floor disorders with botulinum neurotoxin.

Authors:  G Maria; F Cadeddu; D Brisinda; F Brandara; G Brisinda
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

5.  Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction.

Authors:  Heinrich Schulte-Baukloh; Catarina Weiss; Thomas Stolze; Jaqueline Herholz; Burkard Stürzebecher; Kurt Miller; Helmut H Knispel
Journal:  Eur Urol       Date:  2005-07-18       Impact factor: 20.096

6.  Long-term results of augmentation cystoplasty in spinal cord injury patients.

Authors:  E J Chartier-Kastler; P Mongiat-Artus; M O Bitker; M B Chancellor; F Richard; P Denys
Journal:  Spinal Cord       Date:  2000-08       Impact factor: 2.772

7.  Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.

Authors:  Brigitte Schurch; Marianne de Sèze; Pierre Denys; Emmanuel Chartier-Kastler; Francois Haab; Karel Everaert; Pierre Plante; Brigitte Perrouin-Verbe; Catherine Kumar; Stephanie Fraczek; Mitchell F Brin
Journal:  J Urol       Date:  2005-07       Impact factor: 7.450

8.  Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection.

Authors:  Brian L Cohen; Rolando Rivera; Paholo Barboglio; Angelo Gousse
Journal:  J Urol       Date:  2007-03       Impact factor: 7.450

9.  Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience.

Authors:  David E Rapp; Alvaro Lucioni; Erin E Katz; R Corey O'Connor; Glenn S Gerber; Gregory T Bales
Journal:  Urology       Date:  2004-06       Impact factor: 2.649

10.  Prevalence and burden of overactive bladder in the United States.

Authors:  W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein
Journal:  World J Urol       Date:  2002-11-15       Impact factor: 4.226
View more
  3 in total

Review 1.  New insights into the pharmacology of the bladder.

Authors:  Ann T Hanna-Mitchell; Lori A Birder
Journal:  Curr Opin Urol       Date:  2008-07       Impact factor: 2.309

2.  What is the predictive value of urodynamics to reproduce clinical findings of urinary frequency, urge urinary incontinence, and/or stress urinary incontinence?

Authors:  Daniel J Caruso; Prashanth Kanagarajah; Brian L Cohen; Rajinikanth Ayyathurai; Christopher Gomez; Angelo E Gousse
Journal:  Int Urogynecol J       Date:  2010-06-18       Impact factor: 2.894

Review 3.  Botulinum toxin in paediatric urology: a systematic literature review.

Authors:  Ranan DasGupta; Feilim Liam Murphy
Journal:  Pediatr Surg Int       Date:  2008-10-25       Impact factor: 1.827
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.